ATF4 Inhibitors offer unique opportunities
Veltion Therapeutics LLC (VTP) is developing novel, potent and specific inhibitors of the ISR pathway with a focus on inhibiting the activity of ATF4. These anti-tumor agents are being developed specifically for pancreatic cancer and fibrosarcoma. In 2019, an estimated 57,600 in the U.S. were diagnosed with pancreatic cancer which is an essentially lethal disease with a 5-year survival of less than 10%. Soft tissue sarcoma impacts 13,000 individuals every year, with an overall 5-year survival of 40-60%. Current treatments for both modalities have had modest efficacy.